树突状细胞来源外泌体在同源肝细胞癌小鼠模型中诱导肿瘤消退
该研究在三种不同肝细胞癌(HCC)小鼠模型中系统评估了表达甲胎蛋白(AFP)的树突状细胞(DC)来源外泌体(DEXAFP)的疗效。DEXAFP可激发强抗原特异性免疫应答,在异位、原位及致癌物诱导的HCC小鼠中显著延缓肿瘤生长并延长生存期,改善肿瘤微环境;其抗肿瘤作用依赖T细胞。
要点
- DEXAFP在三种HCC小鼠模型中均激发强抗原特异性免疫应答并延缓肿瘤生长。
- DEXAFP治疗组肿瘤部位IFN-γ阳性CD8+ T细胞及IFN-γ、IL-2水平升高,CD25+Foxp3+ Treg细胞及IL-10、TGF-β水平降低。
- 无胸腺裸鼠及CD8+ T细胞清除小鼠中DEXAFP无效,提示T细胞介导其抗肿瘤功能。
核心结论
- 作者认为富含AFP的DEX可激发强抗原特异性抗肿瘤免疫应答并重塑HCC小鼠肿瘤微环境,为HCC免疫治疗提供无细胞疫苗选择。
研究设计与样本
- 研究系统评估了表达AFP的DC来源外泌体(DEXAFP)在三种不同HCC小鼠模型中的效果,监测肿瘤生长与微环境。
主要发现
- DEXAFP在异位、原位及致癌物诱导的HCC小鼠中激发强抗原特异性免疫应答,显著延缓肿瘤生长并延长生存率,这些模型呈现抗原性和病理异质性。
- DEXAFP治疗组肿瘤部位IFN-γ阳性CD8+ T淋巴细胞显著增多,IFN-γ和IL-2水平升高,CD25+Foxp3+ Treg细胞减少,IL-10和TGF-β水平降低。
- 无胸腺裸鼠及CD8+ T细胞清除小鼠中DEXAFP无效,表明T细胞参与其介导的抗肿瘤功能。
- 对DEXAFP治疗的原位HCC小鼠不同时间点动态检测显示,肿瘤抑制与免疫微环境呈正相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Dendritic cell (DC)-derived exosomes (DEXs) form a new class of vaccines for cancer immunotherapy. However, their potency in hepatocellular carcinoma (HCC), a life-threatening malignancy with limited treatment options in the clinic that responds poorly to immunotherapy, remains to be investigated. METHODS: Exosomes derived from α-fetoprotein (AFP)-expressing DCs (DEXAFP) were investigated in three different HCC mouse models systemically. Tumor growth and microenvironment were monitored. RESULTS: DEXAFP elicited strong antigen-specific immune responses and resulted in significant tumor growth retardation and prolonged survival rates in mice with ectopic, orthotopic and carcinogen-induced HCC tumors that displayed antigenic and pathological heterogeneity. The tumor microenvironment was improved in DEXAFP-treated HCC mice, demonstrated by significantly more γ-interferon (IFN-γ)-expressing CD8+ T lymphocytes, elevated levels of IFN-γ and interleukin-2, and fewer CD25+Foxp3+ regulatory T (Treg) cells and decreased levels of interleukin-10 and transforming growth factor-β in tumor sites. Lack of efficacy in athymic nude mice and CD8+ T cell-depleted mice showed that T cells contribute to DEXAFP-mediated antitumor function. Dynamic examination of the antitumor efficacy and the immune microenvironment in DEXAFP-treated orthotopic HCC mice at different time-points revealed a positive correlation between tumor suppression and immune microenvironment. CONCLUSIONS: Our findings provide evidence that AFP-enriched DEXs can trigger potent antigen-specific antitumor immune responses and reshape the tumor microenvironment in HCC mice and thus provide a cell-free vaccine option for HCC immunotherapy. Lay summary: Dendritic cell (DC)-derived exosomes (DEXs) form a new class of vaccines for cancer immunotherapy. However, their potency in hepatocellular carcinoma (HCC) remains unknown. Here, we investigated exosomes from HCC antigen-expressing DCs in three different HCC mouse models and proved their feasibility and capability of treating HCC, and thus provide a cell-free vaccine for HCC immunotherapy.
引用
- Lu Z, Zuo B, Jing R, et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol. 2017. PMID: 28549917. doi:10.1016/j.jhep.2017.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。